Der Biomarker PIK3CA in der Tumorpathologie

Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of action and therapeutic targeting. Nat Rev Cancer 15:7–24 André F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929–1940 Narayan P, Prowell TM, Gao JJ et al (2021) FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res 27:1842–1849 https://www.ema.europa.eu/en/documents/overview/piqray-epar-medicine-overview_de.pdf. Zugegriffen: 12.01.2023 Rugo HS, Raskin K, Schrock AB et al (2022) Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-2115 Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A et al (2019) Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors. Science 366:714–723 Fillbrunn M, Signorovitch J, André F et al (2022) PIK3CA mutation status, progression and survival in advanced HR+ /HER2− breast cancer: meta-analysis of published clinical trials. BMC Cancer 22:1002 Madsen RR, Semple RK (2022) PIK3CA-realted overgrowth: silver bullets from the cancer arsenal? Trends Mol Med 28:255–257